EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC 4.0

Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, “window-of-opportunity” study

Victor Moreno iD, Juan Manuel Sepúlveda iD, David A Reardon, Ángel Pérez-Núñez iD, Pedro González León, Bishoy Hanna, Ellen Filvaroff, Ida Aronchik, Henry Chang, Barbara Amoroso, Marlene Zuraek, Tania Sanchez-Perez und 4 weitere

Neuro-Oncology · 02.06.2023 · 25 (6) · 1113-1122

DOI: 10.1093/neuonc/noac263 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Neuro-Oncology, online erschienen am 01.12.2022. Verfasst von Victor Moreno und 15 weiteren Autor:innen. Beteiligte Einrichtung: START Madrid-FJD, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain. Hauptthemen laut MEDLINE: Glioma, Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Celgene.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The bromodomain and extraterminal protein (BET) inhibitor trotabresib has demonstrated antitumor activity in patients with advanced solid tumors, including high-grade gliomas. CC-90010-GBM-001 (NCT04047303) is a phase I study investigating the pharmacokinetics, pharmacodynamics, and CNS penetration of trotabresib in patients with recurrent high-grade gliomas scheduled for salvage resection.

Methods

Patients received trotabresib 30 mg/day on days 1–4 before surgery, followed by maintenance trotabresib 45 mg/day 4 days on/24 days off after surgery. Primary endpoints were plasma pharmacokinetics and trotabresib concentrations in resected tissue. Secondary and exploratory endpoints included safety, pharmacodynamics, and antitumor activity.

Results

Twenty patients received preoperative trotabresib and underwent resection with no delays or cancelations of surgery; 16 patients received maintenance trotabresib after recovery from surgery. Trotabresib plasma pharmacokinetics were consistent with previous data. Mean trotabresib brain tumor tissue:plasma ratio was 0.84 (estimated unbound partition coefficient [KPUU] 0.37), and modulation of pharmacodynamic markers was observed in blood and brain tumor tissue. Trotabresib was well tolerated; the most frequent grade 3/4 treatment-related adverse event during maintenance treatment was thrombocytopenia (5/16 patients). Six-month progression-free survival was 12%. Two patients remain on treatment with stable disease at cycles 25 and 30.

Conclusions

Trotabresib penetrates the blood–brain-tumor barrier in patients with recurrent high-grade glioma and demonstrates target engagement in resected tumor tissue. Plasma pharmacokinetics, blood pharmacodynamics, and safety were comparable with previous results for trotabresib in patients with advanced solid tumors. Investigation of adjuvant trotabresib + temozolomide and concomitant trotabresib + temozolomide + radiotherapy in patients with newly diagnosed glioblastoma is ongoing (NCT04324840).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GliomaGlioblastomaBrain NeoplasmsHumansTemozolomideDacarbazineAntineoplastic Agents, Alkylating

Stichwörter der Autor:innen

blood–brain-tumor barrierglioblastomapharmacodynamicspharmacokineticstrotabresib

Substanzen

TemozolomideDacarbazineAntineoplastic Agents, Alkylating

Autor:innen und Institutionen

  • START Madrid-FJD, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
  • Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Department of Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Bristol Myers Squibb, Princeton, New Jersey, USA.
  • Bristol Myers Squibb, San Francisco, California, USA.
  • Centre for Innovation and Translational Research Europe, A Bristol Myers Squibb Company, Seville, Spain.

ORCID-Profile: Victor Moreno, Juan Manuel Sepúlveda, Ángel Pérez-Núñez, Michael A Vogelbaum

Förderung

  • Celgene

Zitieren

APA

Moreno, V., Manuel Sepúlveda, J., Reardon, D. A., Pérez-Núñez, Á., González León, P., Hanna, B., Filvaroff, E., Aronchik, I., Chang, H., Amoroso, B., Zuraek, M., Sanchez-Perez, T., Mendez, C., Stephens, D., Nikolova, Z., & Vogelbaum, M. A. (2023). Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, “window-of-opportunity” study. Neuro-Oncology, 25(6), 1113-1122. https://doi.org/10.1093/neuonc/noac263

Vancouver

Moreno V, Manuel Sepúlveda J, Reardon DA, Pérez-Núñez Á, González León P, Hanna B, et al. Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, “window-of-opportunity” study. Neuro-Oncology. 2023;25(6):1113-1122. doi:10.1093/neuonc/noac263

BibTeX
@article{Moreno2023,
  author = {Moreno, Victor and Manuel Sepúlveda, Juan and Reardon, David A and Pérez-Núñez, Ángel and González León, Pedro and Hanna, Bishoy and Filvaroff, Ellen and Aronchik, Ida and Chang, Henry and Amoroso, Barbara and Zuraek, Marlene and Sanchez-Perez, Tania and Mendez, Cristina and Stephens, Daniel and Nikolova, Zariana and Vogelbaum, Michael A},
  title = {Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, “window-of-opportunity” study},
  journal = {Neuro-Oncology},
  year = {2023},
  volume = {25},
  number = {6},
  pages = {1113--1122},
  doi = {10.1093/neuonc/noac263}
}
Kostenlos starten →